Mocetinostat

{{Infobox drug | Watchedfields = changed | verifiedrevid = 470603252 | IUPAC_name = N-(2-Aminophenyl)-4-[[[4-[[[[(1E)-2-cyano-1-ethenyl]oxy]methyl]phenyl]amino]methylidene]-2,5-cyclohexadien-1-ylidene]benzamide | image = | tradename = | Drugs.com = | pregnancy_category = | legal_status = Investigational | routes_of_administration = | bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion = | CAS_number = 726169-73-9 | ATC_prefix = | ATC_suffix = | PubChem = 9931954 | DrugBank = | ChemSpider = 8107583 | UNII = 7K33JQL57R | KEGG = | ChEMBL = CHEMBL354536 | synonyms = MGCD0103 }}

Mocetinostat is an experimental drug and histone deacetylase inhibitor currently under investigation for its potential use in the treatment of various cancers, including Hodgkin's lymphoma, acute myeloid leukemia (AML), and solid tumors. It is known by its chemical name, N-(2-Aminophenyl)-4-[[[4-[[[[(1E)-2-cyano-1-ethenyl]oxy]methyl]phenyl]amino]methylidene]-2,5-cyclohexadien-1-ylidene]benzamide, and also by its developmental code, MGCD0103.

Mechanism of Action

Mocetinostat functions by inhibiting the activity of certain enzymes known as histone deacetylases (HDACs). These enzymes play a crucial role in the regulation of gene expression by altering the chromatin structure, which can affect cell cycle progression and survival. By inhibiting HDACs, mocetinostat can induce apoptosis (programmed cell death) and inhibit the proliferation of cancer cells.

Clinical Trials

Mocetinostat has been involved in several clinical trials assessing its efficacy and safety. It has been studied as a monotherapy and in combination with other chemotherapy agents. The outcomes of these trials are critical for determining the potential of mocetinostat as a viable therapeutic option in oncology.

Pharmacokinetics

Details on the pharmacokinetics of mocetinostat, such as its bioavailability, metabolism, and excretion, are essential for understanding its behavior in the human body. These factors influence the dosage and administration strategies of the drug.

Regulatory Status

As of the last update, mocetinostat is classified as an investigational drug and has not received approval from regulatory bodies such as the Food and Drug Administration (FDA) for general medical use. It remains in various phases of clinical trials to establish its safety and efficacy profiles.

Potential Side Effects

Like all therapeutic agents, mocetinostat may cause side effects. The nature and severity of these side effects can vary among individuals and depend on several factors, including the dosage and duration of treatment. Common side effects observed in trials include fatigue, nausea, and changes in blood counts.

Future Prospects

The future development of mocetinostat depends on the outcomes of ongoing and future clinical trials. Positive results could lead to further studies and potentially to regulatory approval for use in specific types of cancer.